Echo Therapeutics Announces Successful Completion Of Clinical Trial For Prelude(TM) SkinPrep System And 4 percent Lidocaine Cream
Echo Therapeutics, Inc. has announced the completion of a clinical study of Prelude. This clinical study was designed to evaluate the ability of Prelude to ablate the skin prior to the application of OTC 4% lidocaine cream for faster-acting local dermal anesthesia. As a result of the clinical trial, Echo now expects the submission of a 510(k) premarket notification to the United States Food and Drug Administration (FDA) in the near future.
Read the full story here
-
First Patient Treated With Valiant(R) Thoracic Stent Graft In Aortic Dissection Trial
PreMD NSE appeal upheld by FDA
Epocal Announces FDA Clearance Of Lactate Test
Angiotech Announces Long-Term Data Show Advantages For Taxus(R) Liberté(R) Stent In Small Vessels And Long Lesions
Roche Gets FDA Ok For LightCycle Test
